10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Mar 11, 2024

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring The findings were presented in a late-breaking research abstract at the 2024 American Academy of Dermatology (AAD) Annual...

10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring

Aug 16, 2023

10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring August 16, 2023 SAN DIEGO – August 16, 2023 – 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies,...

10xBio Provides Update on Patent Portfolio

Jul 13, 2023

10xBio Provides Update on Patent Portfolio July 15, 2023 SAN DIEGO (July 15, 2023) – 10xBio, LLC, a privately-held biotechnology company, announces that in the past 24 months it has been issued 3 patents from the U.S. Patent and Trademark Office. These patents broadly...

10xBio Completes Series B Financing

Aug 23, 2021

10xBio Completes Series B Financing August 23, 2021 SAN DIEGO (August 23, 2021) – 10xBio, LLC, a privately-held biotechnology company, completed a Series B financing from a select group of partners and private investors. Capital raised totaled approximately...

Hugel Acquires Phase 2 U.S. Clinical Data to 10XB101 and Exercises China Option for the Drug Product

Aug 12, 2021

Hugel Acquires Phase 2 U.S. Clinical Data to 10XB101 and Exercises China Option for the Drug Product August 12, 2021 SAN DIEGO (August 12, 2021) – 10xBio, LLC, a privately-held biotechnology company, announces that its Korean Partner, Hugel, Inc., has acquired rights...

10xBio Announces the Completion of Phase 2 Clinical Trial of 10XB101

Aug 3, 2021

10xBio Announces the Completion of Phase 2 Clinical Trial of 10XB101 August 3, 2021 SAN DIEGO (August 3, 2021) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 2 dose escalation study of its novel injectable drug...